FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178110106> ?p ?o ?g. }

• W3178110106 endingPage "779" @default.
• W3178110106 startingPage "765" @default.
• W3178110106 abstract "The potential for new chemical entities to inhibit the major cytochrome P450 (CYP) isoforms is routinely evaluated to minimize the risk of developing drugs with drug–drug interaction liabilities. CYP inhibition assays are routinely performed in a high-throughput format to efficiently screen large numbers of compounds. In evaluating a time-saving assay using diclofenac as the CYP2C9 probe substrate, a discrepancy was observed in which minimal inhibition was detected using diclofenac whereas using (S)-warfarin resulted in potent inhibition, supporting the presence of dual-binding sites in the relatively large CYP2C9 active site cavity. These observations provided further insights into explaining the reported ineffective inactivation of CYP2C9 for the pan-CYP inactivator 1-aminobenzotriazole (ABT). Mechanistic reversible and time-dependent inhibitionInhibitiontime dependent inhibition experiments revealed that the ineffective CYP2C9 inactivation by ABT was also probe-dependent, with utilization of (S)-warfarin as the probe substrate resulting in more potent CYP2C9 inhibition by ABT compared to diclofenac. Addition of (S)-warfarin to the reversible and time-dependent inhibition experiments between ABT and diclofenac resulted in an attenuation of the inhibitory effects of ABT on CYP2C9-mediated diclofenac metabolism. Molecular dockingMolecular docking studies further confirmed that (S)-warfarin and diclofenac preferentially bind in different regions of the CYP2C9 active site, with (S)-warfarin occupying a distal “warfarin-binding pocket” and diclofenac occupying a binding site close to the active heme moiety. ABT preferentially binds in the distal warfarin-binding pocket, supporting that diclofenac is minimally deterred from access to the CYP2C9 active site in the presence of ABT, thus resulting in minimal inactivation. Simultaneously docking of (S)-warfarin and ABT revealed that (S)-warfarin outcompetes ABT for the distal binding site and results in the binding of ABT to the CYP2C9 active site, supporting the observations of potent inactivation of CYP2C9 when (S)-warfarin is the probe substrate. These results highlight that probe selection is crucial when evaluating CYP inhibition potential, and it is recommended that multiple probes be utilized for CYP2C9, similar to the approach routinely employed for CYP3A4. Further, utilization of ABT as a pan-inhibitor of CYP activity for investigational compounds, both in vitro and in vivo, should be accompanied with the understanding that residual CYP-mediated oxidative metabolism could potentially be observed for CYP2C9 substrates and should not necessarily be attributed to non-P450-mediated metabolism." @default.
• W3178110106 created "2021-07-19" @default.
• W3178110106 creator A5033491672 @default.
• W3178110106 creator A5060581165 @default.
• W3178110106 date "2021-01-01" @default.
• W3178110106 modified "2023-10-15" @default.
• W3178110106 title "Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT)" @default.
• W3178110106 cites W14345246 @default.
• W3178110106 cites W1508691659 @default.
• W3178110106 cites W1975206909 @default.
• W3178110106 cites W1976225191 @default.
• W3178110106 cites W1979873522 @default.
• W3178110106 cites W1980308226 @default.
• W3178110106 cites W1987802481 @default.
• W3178110106 cites W1997049949 @default.
• W3178110106 cites W2001968807 @default.
• W3178110106 cites W2009313893 @default.
• W3178110106 cites W2010427019 @default.
• W3178110106 cites W2017618675 @default.
• W3178110106 cites W2031011202 @default.
• W3178110106 cites W2034029745 @default.
• W3178110106 cites W2043515466 @default.
• W3178110106 cites W2046255313 @default.
• W3178110106 cites W2052321618 @default.
• W3178110106 cites W2064650404 @default.
• W3178110106 cites W2074192127 @default.
• W3178110106 cites W2078983260 @default.
• W3178110106 cites W2093107388 @default.
• W3178110106 cites W2102551031 @default.
• W3178110106 cites W2109634874 @default.
• W3178110106 cites W2111668019 @default.
• W3178110106 cites W2116545934 @default.
• W3178110106 cites W2134224845 @default.
• W3178110106 cites W2137538945 @default.
• W3178110106 cites W2139348717 @default.
• W3178110106 cites W2141115118 @default.
• W3178110106 cites W2142068240 @default.
• W3178110106 cites W2153936380 @default.
• W3178110106 cites W2154001781 @default.
• W3178110106 cites W2158468919 @default.
• W3178110106 cites W2164970832 @default.
• W3178110106 cites W2266651864 @default.
• W3178110106 cites W2329131083 @default.
• W3178110106 cites W2605228520 @default.
• W3178110106 cites W2761920992 @default.
• W3178110106 cites W2779604619 @default.
• W3178110106 doi "https://doi.org/10.1007/978-1-0716-1554-6_28" @default.
• W3178110106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34272716" @default.
• W3178110106 hasPublicationYear "2021" @default.
• W3178110106 type Work @default.
• W3178110106 sameAs 3178110106 @default.
• W3178110106 citedByCount "2" @default.
• W3178110106 countsByYear W31781101062023 @default.
• W3178110106 crossrefType "book-chapter" @default.
• W3178110106 hasAuthorship W3178110106A5033491672 @default.
• W3178110106 hasAuthorship W3178110106A5060581165 @default.
• W3178110106 hasConcept C107824862 @default.
• W3178110106 hasConcept C159110408 @default.
• W3178110106 hasConcept C164705383 @default.
• W3178110106 hasConcept C181199279 @default.
• W3178110106 hasConcept C185592680 @default.
• W3178110106 hasConcept C2776301958 @default.
• W3178110106 hasConcept C2779161974 @default.
• W3178110106 hasConcept C2779826273 @default.
• W3178110106 hasConcept C3946865 @default.
• W3178110106 hasConcept C41183919 @default.
• W3178110106 hasConcept C41685203 @default.
• W3178110106 hasConcept C526171541 @default.
• W3178110106 hasConcept C55493867 @default.
• W3178110106 hasConcept C71924100 @default.
• W3178110106 hasConcept C86803240 @default.
• W3178110106 hasConcept C98274493 @default.
• W3178110106 hasConceptScore W3178110106C107824862 @default.
• W3178110106 hasConceptScore W3178110106C159110408 @default.
• W3178110106 hasConceptScore W3178110106C164705383 @default.
• W3178110106 hasConceptScore W3178110106C181199279 @default.
• W3178110106 hasConceptScore W3178110106C185592680 @default.
• W3178110106 hasConceptScore W3178110106C2776301958 @default.
• W3178110106 hasConceptScore W3178110106C2779161974 @default.
• W3178110106 hasConceptScore W3178110106C2779826273 @default.
• W3178110106 hasConceptScore W3178110106C3946865 @default.
• W3178110106 hasConceptScore W3178110106C41183919 @default.
• W3178110106 hasConceptScore W3178110106C41685203 @default.
• W3178110106 hasConceptScore W3178110106C526171541 @default.
• W3178110106 hasConceptScore W3178110106C55493867 @default.
• W3178110106 hasConceptScore W3178110106C71924100 @default.
• W3178110106 hasConceptScore W3178110106C86803240 @default.
• W3178110106 hasConceptScore W3178110106C98274493 @default.
• W3178110106 hasLocation W31781101061 @default.
• W3178110106 hasOpenAccess W3178110106 @default.
• W3178110106 hasPrimaryLocation W31781101061 @default.
• W3178110106 hasRelatedWork W2025668168 @default.
• W3178110106 hasRelatedWork W2039577410 @default.
• W3178110106 hasRelatedWork W2105369514 @default.
• W3178110106 hasRelatedWork W2162442372 @default.
• W3178110106 hasRelatedWork W2353264395 @default.
• W3178110106 hasRelatedWork W2379023273 @default.
• W3178110106 hasRelatedWork W2729913079 @default.

• next